(2-{4-[3-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-ylcarbamoyl}-ethyl)-carbamic acid t-butylester → Allitinib metabolite M6

HRID 1675206

Reaktionsgleichung

Reaktionsgleichung von HRID 1675206
NCCC([NH:6][C:7]1[CH:8]=[C:9]2[C:14](=[CH:15][CH:16]=1)[N:13]=[CH:12][N:11]=[C:10]2[NH:17][C:18]1[CH:23]=[CH:22][C:21]([O:24][CH2:25][C:26]2[CH:31]=[CH:30][CH:29]=[C:28]([F:32])[CH:27]=2)=[C:20]([Cl:33])[CH:19]=1)=O.C(OC(=O)NCCC(=O)NC1C=C2C(=CC=1)N=CN=C2NC1C=CC(OC2C=NC(C)=CC=2)=C(C)C=1)(C)(C)C>>[Cl:33][C:20]1[CH:19]=[C:18]([NH:17][C:10]2[C:9]3[C:14](=[CH:15][CH:16]=[C:7]([NH2:6])[CH:8]=3)[N:13]=[CH:12][N:11]=2)[CH:23]=[CH:22][C:21]=1[O:24][CH2:25][C:26]1[CH:31]=[CH:30][CH:29]=[C:28]([F:32])[CH:27]=1

Komponenten

3

Edukt 2

HCID 11699363(2-{4-[3-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-ylcarbamoyl}-ethyl)-carbamic acid t-butylesterHCID 673341233-Amino-N-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)propanamide

Produkt 1

HCID 53630477Allitinib metabolite M6

Versuchsvorschrift

The procedure of (20-1) of Example 20 was repeated except for using 1 g of the compound obtained in Example 49 instead of the compound obtained in (1-4) of Example 1 to obtain the title compound (0.79 g, 98%).

Quellen und Nachweise

ORD-Eintrag
ord-9d8f1d311f49461e828beaf4a7b7b461
Quelldatensatz
uspto-grants-2011_08
Patentnummer
US08003658B2

Verknüpfte Notizen

Wird geladen…